|
Rineterkib hydrochloride
|
RINETERKIBHCL
|
1715025-34-5
|
|
Erastin
|
ERASTIN
|
571203-78-6
|
|
Betrixaban
|
貝曲西班
|
330942-05-7
|
|
Nintedanib esylate
|
尼達尼布乙磺酸鹽
|
656247-18-6
|
|
Ulixertinib
|
4-[5-氯-2-[(1-甲基乙基)氨基]-4-吡啶基]-N-[(1S)-1-(3-氯苯基)-2-羥基乙基]-1H-吡咯-2-甲酰胺
|
869886-67-9
|
|
KHS101 hydrochloride
|
鹽酸KHS101
|
1784282-12-7
|
|
PROTAC FAK degrader 1
|
PROTAC FAK degrader 1
|
2301916-69-6
|
|
MAP855
|
化合物 MAP855
|
1660107-77-6
|
|
VX-11e
|
VX11E
|
896720-20-0
|
|
Apixaban-13C,d3
|
阿哌沙班雜質(zhì)13C-D3
|
1261393-15-0
|
|
Linagliptin-d4
|
利拉利汀雜質(zhì)
|
2140263-92-7
|
|
EF24
|
3,5-Bis[(2-fluorophenyl)Methylene]-4-piperidinone
|
342808-40-6
|
|
Liproxstatin-1 HCl(free base)
|
利普司他丁-1
|
950455-15-9
|
|
ML-210
|
[4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone
|
1360705-96-9
|
|
FIIN-2
|
FIIN-2
|
1633044-56-0
|
|
AX-15836
|
2035509-96-5
|
2035509-96-5
|
|
MMRi62
|
7-((2,3-二氯苯基)(吡啶-2-基氨基)甲基)喹啉-8-醇
|
352693-80-2
|
|
Rineterkib
|
ERK-IN-1 (COMPOUND B)
|
1715025-32-3
|
|
SWE101
|
SWE101
|
2376322-12-0
|
|
DMU-212
|
3,4,5,4'-四甲氧基二苯乙烯
|
134029-62-2
|
|
NSC12
|
CS-2161
|
102586-30-1
|
|
CC-90003
|
1621999-82-3
|
1621999-82-3
|
|
ODM-203
|
ODM203
|
1430723-35-5
|
|
E7090 succinate
|
化合物 E7090 SUCCINATE
|
1879965-80-6
|
|
Pioglitazone-d4
|
匹格列酮-D4
|
1134163-29-3
|
|
Ozagrel
|
奧扎格雷
|
82571-53-7
|
|
FGFR-IN-1
|
|
1513860-41-7
|
|
sEH inhibitor-7
|
化合物 SEH INHIBITOR-7
|
340221-20-7
|
|
Anti-inflammatory agent 35
|
化合物T64358
|
2293951-00-3
|
|
PND-1186
|
PND1186
|
1061353-68-1
|
|
JK-P3
|
3,4-二甲氧基-N-(5-苯基-1H-吡唑-3-基)苯甲酰胺
|
942655-44-9
|
|
BI-4464
|
BI 4464)
|
1227948-02-8
|
|
BMS-962212
|
BMS-962212
|
1430114-34-3
|
|
CK2/ERK8-IN-1
|
CK2/ERK8-IN-1
|
1085822-09-8
|
|
OncoFAP
|
190327
|
2639365-69-6
|
|
Lidocaine hydrochloride
|
鹽酸利多卡因
|
73-78-9
|
|
PD-166866
|
PD-166866
|
192705-79-6
|
|
Eugenol-d3
|
Eugenol-d3
|
1335401-17-6
|
|
FIN56
|
FIN56
|
1083162-61-1
|
|
URB597
|
URB597
|
546141-08-6
|
|
Rogaratinib
|
羅加替尼
|
1443530-05-9
|
|
JWG-071
|
JWG-071
|
2250323-50-1
|
|
CP-547632 hydrochloride
|
CP-547632 (hydrochloride)
|
252003-71-7
|
|
Ulixertinib (hydrochloride)
|
BVD-523 鹽酸鹽
|
1956366-10-1
|
|
Fisogatinib
|
BLU554
|
1707289-21-1
|
|
E7090
|
E-7090
|
1622204-21-0
|
|
Pemigatinib
|
培米加替尼
|
1513857-77-6
|
|
DY131
|
N'-(4-(二乙氨基)亞芐基)-4-羥基苯甲酰肼
|
95167-41-2
|
|
Ifebemtinib
|
1227948-82-4
|
1227948-82-4
|
|
Alogliptin Benzoate
|
苯甲酸阿格列汀
|
850649-62-6
|
|
RLX-33
|
RLX-33
|
2784577-71-3
|
|
iFSP1
|
1-amino-3-(4-methylphenyl)pyrido[1,2-a]benzimidazole-2,4-dicarbonitrile
|
150651-39-1
|
|
Pifithrin-β hydrobromide
|
環(huán)狀抑制劑-Α氫溴酸鹽
|
511296-88-1
|
|
MB05032
|
2-氨基-5-異丁基-4-[5-膦?；?2-呋喃基]噻唑
|
261365-11-1
|
|
R1530
|
5-(2-氯苯基)-7-氟-1,2-二氫-8-甲氧基-3-甲基吡唑并[3,4-B][1,4]苯并二氮雜卓
|
882531-87-5
|
|
XMD17-109
|
XMD17 109
|
1435488-37-1
|
|
Setanaxib
|
2-(2-氯苯基)-4-[3-(二甲基氨基)苯基]-5-甲基-1H-吡唑并[4,3-C]吡啶-3,6(2H,5H)-二酮
|
1218942-37-0
|
|
Ravoxertinib
|
GDC-0994
|
1453848-26-4
|
|
FGFR4-IN-1
|
CS-2343
|
1708971-72-5
|
|
KO-947
|
KO-947
|
1695533-89-1
|
|
ASTX029
|
ASTX-029
|
2095719-92-7
|
|
BAY885
|
BAY-885
|
2307249-33-6
|
|
Linagliptin
|
利拉利汀
|
668270-12-0
|
|
FR 180204
|
FR180204
|
865362-74-9
|
|
BIX02188
|
(3Z)-3-[[[3-[(二甲基氨基)甲基]苯基]氨基]苯亞甲基]-2,3-二氫-2-氧代-1H-吲哚-6-甲酰胺
|
334949-59-6
|
|
Edoxaban tosylate
|
伊多塞班對甲苯磺酸鹽
|
480449-71-6
|
|
NADPH tetrasodium salt
|
還原型輔酶Ⅱ四鈉
|
2646-71-1
|
|
BI-3663
|
BI-3663
|
2341740-84-7
|
|
Deferasirox
|
地拉羅司
|
201530-41-8
|
|
GSK215
|
GSK215
|
2743427-26-9
|
|
GPX4-IN-3
|
化合物 GPX4-IN-3
|
2761004-85-5
|
|
CP-547632
|
3-[(4-溴-2,6-二氟芐基)氧基]-5-[3-[4-(吡咯烷-1-基)丁基]脲基]異噻唑-4-甲酰胺
|
252003-65-9
|
|
SSR128129E
|
SSR128129E
|
848318-25-2
|
|
Defactinib
|
地法替尼
|
1073154-85-4
|
|
Tyrosine kinase-IN-1
|
TYROSINE KINASE-IN-1
|
705946-27-6
|
|
BLU9931
|
BLU 9931
|
1538604-68-0
|
|
GSK2256098
|
GSK-2256098
|
1224887-10-8
|
|
GSK2256294A
|
SEH抑制劑(GSK2256294A)
|
1142090-23-0
|
|
ERK1/2 inhibitor 1
|
ERK1/2 INHIBITOR 1
|
2095719-90-5
|
|
Erastin2
|
4(3H)-Quinazolinone, 2-[[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]methyl]-3-[4-(1-methylethoxy)[1,1'-biphenyl]-3-yl]-
|
1695533-44-8
|
|
Dopamine-d5 (hydrochloride)
|
鹽酸多巴胺:(2 - (3 4-DIHYDROXYPHENYL)
|
2193106-55-5
|
|
Lidocaine
|
利多卡因
|
137-58-6
|
|
(Z)-Orantinib
|
SU 6668
|
210644-62-5
|
|
Darexaban
|
N-[2-羥基-6-(4-甲氧基苯甲酰氨基)苯基]-4-(4-甲基-1,4-二氮雜庚烷-1-基)苯甲酰胺
|
365462-23-3
|
|
Pioglitazone
|
匹格列酮
|
111025-46-8
|
|
AR-9281
|
1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea
|
913548-29-5
|
|
LM22B-10
|
2-[[4-[[4-[BIS-(2-HYDROXYETHYL)-AMINO]-PHENYL]-(4-CHLORO-PHENYL)-METHYL]-PHENYL]-(2-HYDROXY-ETHYL)-AMINO]-ETHANOL
|
342777-54-2
|
|
Tizaterkib
|
CS-2696
|
2097416-76-5
|
|
Conteltinib
|
CONTELTINIB (CT-707)
|
1384860-29-0
|
|
(rel)-AR234960
|
(rel)-AR234960
|
1408311-94-3
|
|
CPL304110
|
化合物 CPL304110
|
1627826-19-0
|
|
Gunagratinib
|
GUNAGRATINIB
|
2211082-53-8
|
|
UAMC-3203 hydrochloride
|
UAMC-3203 HYDROCHLORIDE
|
2271358-65-5
|
|
ERK-IN-3
|
ASN007; ASN-007; ASN 007;
|
2055597-12-9
|
|
FAP-2286
|
FAP2286
|
2581741-18-4
|
|
FAPI-34
|
FAPI-34
|
2374782-07-5
|
|
FAPI-46
|
FAPI-46
|
2374782-04-2
|
|
Alogliptin-d3
|
Alogliptin-d3
|
1133421-35-8
|
|
Asundexian
|
ASUNDEXIAN
|
2064121-65-7
|
|
BMS-309403 sodium
|
BMS-309403 SODIUM
|
2802523-05-1
|